In the past week, WGS stock has gone up by 0.15%, with a monthly decline of -6.34% and a quarterly surge of 76.24%. The volatility ratio for the week is 6.89%, and the volatility levels for the last 30 days are 7.94% for GeneDx Holdings Corp The simple moving average for the last 20 days is -1.43% for WGS’s stock, with a simple moving average of 94.04% for the last 200 days.
Is It Worth Investing in GeneDx Holdings Corp (NASDAQ: WGS) Right Now?
Moreover, the 36-month beta value for WGS is 2.10. Analysts have varying opinions on the stock, with 3 analysts rating it as a “buy,” 0 as “overweight,” 3 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for WGS is 21.97M and currently, short sellers hold a 9.78% of that float. On December 27, 2024, WGS’s average trading volume was 625.22K shares.
WGS) stock’s latest price update
GeneDx Holdings Corp (NASDAQ: WGS) has experienced a decline in its stock price by -5.08 compared to its previous closing price of 79.45. However, the company has seen a gain of 0.15% in its stock price over the last five trading days. businesswire.com reported 2024-12-16 that STAMFORD, Conn.–(BUSINESS WIRE)–GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in the 43rd Annual J.P. Morgan Healthcare Conference from January 12-16 in San Francisco, CA. Management will participate in a presentation on Wednesday, January 15, 2025, at 4:30 p.m. PT. Live and archived webcasts will be available on the “Events” section of the GeneDx investor relations website at ir.genedx.
Analysts’ Opinion of WGS
Many brokerage firms have already submitted their reports for WGS stocks, with Wells Fargo repeating the rating for WGS by listing it as a “Equal Weight.” The predicted price for WGS in the upcoming period, according to Wells Fargo is $34 based on the research report published on August 28, 2024 of the current year 2024.
Craig Hallum, on the other hand, stated in their research note that they expect to see WGS reach a price target of $43. The rating they have provided for WGS stocks is “Buy” according to the report published on July 10th, 2024.
Jefferies gave a rating of “Hold” to WGS, setting the target price at $21 in the report published on June 03rd of the current year.
WGS Trading at 2.70% from the 50-Day Moving Average
After a stumble in the market that brought WGS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -15.37% of loss for the given period.
Volatility was left at 7.94%, however, over the last 30 days, the volatility rate increased by 6.89%, as shares sank -5.51% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +23.48% upper at present.
During the last 5 trading sessions, WGS fell by -0.33%, which changed the moving average for the period of 200-days by +601.40% in comparison to the 20-day moving average, which settled at $76.49. In addition, GeneDx Holdings Corp saw 2642.36% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at WGS starting from Stueland Katherine, who sale 10,501 shares at the price of $76.75 back on Dec 16 ’24. After this action, Stueland Katherine now owns 71,146 shares of GeneDx Holdings Corp, valued at $805,995 using the latest closing price.
Feeley Kevin, the CHIEF FINANCIAL OFFICER of GeneDx Holdings Corp, sale 3,728 shares at $76.75 during a trade that took place back on Dec 16 ’24, which means that Feeley Kevin is holding 28,200 shares at $286,139 based on the most recent closing price.
Stock Fundamentals for WGS
Current profitability levels for the company are sitting at:
- -0.2 for the present operating margin
- 0.54 for the gross margin
The net margin for GeneDx Holdings Corp stands at -0.31. The total capital return value is set at -0.16. Equity return is now at value -36.40, with -20.21 for asset returns.
Based on GeneDx Holdings Corp (WGS), the company’s capital structure generated 0.2 points at debt to capital in total, while cash flow to debt ratio is standing at -1.06. The debt to equity ratio resting at 0.25. The interest coverage ratio of the stock is -16.48.
Currently, EBITDA for the company is -136.46 million with net debt to EBITDA at -1.01. When we switch over and look at the enterprise to sales, we see a ratio of 8.0. The receivables turnover for the company is 6.94for trailing twelve months and the total asset turnover is 0.65. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.41.
Conclusion
To wrap up, the performance of GeneDx Holdings Corp (WGS) has been better in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
